Amgen Inc.
Amgen Inc. Issued $4.0 Billion of Senior Notes
Summary
On February 17, 2026, Amgen Inc. issued $4.0 billion aggregate principal amount of Senior Notes due in 2031, 2036, 2046, and 2056. These notes carry interest rates of 4.200%, 4.850%, 5.500%, and 5.650% respectively and are payable semi-annually. The net proceeds from the offering were approximately $3.96 billion, after deducting underwriters' discounts and estimated offering expenses.
Profitelligence Alerts
Get alerts for AMGN
Be first to know when Amgen Inc. files with the SEC.
Filing Categories
Advertisement
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Official SEC Documents
Advertisement